Trevena, Inc (TRVN) Covered Calls

Trevena, Inc covered calls Trevena Inc is a clinical stage biopharmaceutical company. The Company discovers, develops and commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.

You can sell covered calls on Trevena, Inc to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TRVN (prices last updated Tue 4:16 PM ET):

Trevena, Inc (TRVN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
1.58 -0.02 1.58 1.60 1.3M - 0.1B
Covered Calls For Trevena, Inc (TRVN)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Apr 18 2.5 0.05 1.55 3.2% 48.7%
May 17 2.5 0.00 1.60 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Trevena, Inc. is a clinical stage biopharmaceutical company, which discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors. Its product pipeline consists of TRV027, which is an intravenous drug for the treatment of acute heart failure in combination with standard diuretic therapy; TRV130, which is an intravenous G protein biased ligand that targets the mu opioid receptor; TRV734, which is a follow-on program to the TRV130 mu opioid biased ligand program, and is expected to have pharmacokinetics amenable to chronic oral administration; and Delta Opiod. The company was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in King of Prussia, PA.